XKRX
196170
Market cap12bUSD
Jun 18, Last price
369,500.00KRW
1D
-0.94%
1Q
4.53%
Jan 2017
1,028.24%
IPO
1,527.75%
Name
Alteogen Inc
Chart & Performance
P/E
306.74
P/S
185.66
EPS
1,204.59
Div Yield, %
—
Shrs. gr., 5y
2.13%
Rev. gr., 5y
28.61%
Revenues
102.85b
+6.56%
Net income
62.25b
P
CFO
53.04b
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ALTEOGEN Inc., a biotechnology firm, specializes in advancing long-acting biobetters, its own antibody-drug conjugates (ADCs), and antibody biosimilars. The company is actively progressing ALT-P1, a long-acting human growth hormone currently undergoing Phase IIa clinical evaluation, and ALT-Q2, a long-acting active form of coagulation factor VII designed for hemophilia treatment, leveraging its proprietary NexP platform. Additionally, ALTEOGEN is further advancing ALT-P7, a precision oncology treatment for breast and gastric cancers presently in Phase I clinical trials, and ALT-Q5, an ADC targeting ovarian cancer, utilizing its NexMab ADC platform. The company also engages in strategic collaborations, including one with Kissei Pharmaceutical for the advancement of Aflibercept, which has successfully concluded preclinical testing. Another partnership is with Cristalia for Trastuzumab, currently in Phase II clinical trials for breast cancer treatment. Established in 2008, ALTEOGEN Inc. maintains its headquarters in Daejeon, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||